Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University / Winship Cancer Institute
Atlanta, Georgia, United States
- University of Massachusetts Medical Center
Worcester, Massachusetts, United States
- New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Ohio State University
Columbus, Ohio, United States
- University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2012
- Primary completion
- 30 Dec 2016
- Completion
- 30 Dec 2016
- Last update posted
- 17 Aug 2017
- Registered enrollment
- 49
- Registry id
- NCT01606579
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.